Imbach Patricia, Lang Marc, García-Echeverría Carlos, Guagnano Vito, Noorani Maria, Roesel Johannes, Bitsch Francis, Rihs Grety, Furet Pascal
Novartis Institutes for BioMedical Research, WKL-136.4.25, CH-4002 Basel, Switzerland.
Bioorg Med Chem Lett. 2007 Jan 15;17(2):358-62. doi: 10.1016/j.bmcl.2006.10.047. Epub 2006 Oct 24.
A series of beta-lactam derivatives has been designed and synthesized to inhibit the chymotrypsin-like activity of the human 20S proteasome. The most potent compounds of this new structural class of beta-subunit selective 20S proteasome inhibitors exhibit IC50 values in the low-nanomolar range and show good selectivity over the trypsin-like and post-glutamyl-peptide hydrolytic activities of the enzyme.
已设计并合成了一系列β-内酰胺衍生物,以抑制人20S蛋白酶体的类胰凝乳蛋白酶活性。这类新型β亚基选择性20S蛋白酶体抑制剂中最有效的化合物,其IC50值在低纳摩尔范围内,并且对该酶的类胰蛋白酶活性和谷氨酰胺后肽水解活性具有良好的选择性。